Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Arcturus Therapeutics Dividend Announcement
• Arcturus Therapeutics announced a semi annually dividend of $0.01 per ordinary share which will be made payable on 2013-01-15. Ex dividend date: 2013-01-08
• Arcturus Therapeutics's trailing twelve-month (TTM) dividend yield is -%
Arcturus Therapeutics Dividend History
| Ex-Div date | Dividend amount | Dividend type | Pay date |
|---|---|---|---|
| 2013-01-08 | $0.01 | semi annually | 2013-01-15 |
| 2013-01-04 | $0.01 | semi annually | 2013-01-15 |
| 2012-12-05 | $0.01 | semi annually | 2012-12-15 |
| 2012-11-06 | $0.01 | semi annually | 2012-11-15 |
| 2012-10-03 | $0.01 | semi annually | 2012-10-15 |
| 2012-09-05 | $0.01 | semi annually | 2012-09-15 |
| 2012-08-06 | $0.01 | semi annually | 2012-08-15 |
| 2012-07-03 | $0.01 | semi annually | 2012-07-15 |
| 2012-06-06 | $0.01 | semi annually | 2012-06-15 |
| 2012-05-04 | $0.01 | semi annually | 2012-05-15 |
| 2012-04-03 | $0.01 | semi annually | 2012-04-15 |
| 2012-03-06 | $0.00 | semi annually | 2012-03-15 |
Arcturus Therapeutics Dividend per year
Arcturus Therapeutics Dividend Yield
Arcturus Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Arcturus Therapeutics stock? Use our calculator to estimate your expected dividend yield:
Arcturus Therapeutics Financial Ratios
Arcturus Therapeutics Dividend FAQ
1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.
2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.
3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.
4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.
5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Place an order: Use the brokerage's trading platform to place an order to buy Arcturus Therapeutics stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.